Abcam (ABCZY) Rating Lowered to Hold at Zacks Investment Research

Abcam (OTCMKTS:ABCZY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday.

According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “

Shares of Abcam (ABCZY) traded up $0.45 during trading on Monday, reaching $16.92. 1,400 shares of the company’s stock traded hands, compared to its average volume of 868. Abcam has a one year low of $9.76 and a one year high of $16.75.

ILLEGAL ACTIVITY NOTICE: “Abcam (ABCZY) Rating Lowered to Hold at Zacks Investment Research” was first published by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/22/abcam-abczy-rating-lowered-to-hold-at-zacks-investment-research.html.

Get a free copy of the Zacks research report on Abcam (ABCZY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply